About this Journal Submit a Manuscript Table of Contents
International Journal of Endocrinology
Volume 2012 (2012), Article ID 837187, 5 pages
Clinical Study

Bone Demineralization in Postmenopausal Women: Role of Anamnestic Risk Factors

Section of Endocrinology, Andrology and Internal Medicine, Department of Medical and Pediatric Sciences, University of Catania, Policlinico, 95123 Catania, Italy

Received 8 April 2012; Accepted 13 June 2012

Academic Editor: Ajai Kumar Srivastav

Copyright © 2012 Sandro La Vignera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Garnero, E. Hausherr, M. C. Chapuy et al., “Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study,” Journal of Bone and Mineral Research, vol. 11, no. 10, pp. 1531–1538, 1996. View at Scopus
  2. L. Mosekilde, F. Melsen, J. P. Bagger, O. Myhere-Jensen, and N. S. Sorensen, “Bone changes in hyperthyroidism: interrelationships between bone morphometry. Thyroid function and calcium phosphorus metabolism,” Acta Endocrinologica, vol. 85, no. 3, pp. 515–525, 1977. View at Scopus
  3. J. Foldes and P. Lakatos, “Thyroid and osteoporosis,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 23, pp. 690–692, 1996.
  4. L. Mosekilde, E. F. Eriksen, and P. Charles, “Effects of thyroid hormones on bone and mineral metabolism,” Endocrinology and Metabolism Clinics of North America, vol. 19, no. 1, pp. 35–63, 1990. View at Scopus
  5. R. D. Harvey, K. C. McHardy, I. W. Reid et al., “Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers,” Journal of Clinical Endocrinology and Metabolism, vol. 72, no. 6, pp. 1189–1194, 1991. View at Scopus
  6. S. L. Greenspan and F. S. Greenspan, “The effect of thyroid hormone on skeletal integrity,” Annals of Internal Medicine, vol. 130, no. 9, pp. 750–758, 1999. View at Scopus
  7. P. Vestergaard and L. Mosekilde, “Hyperthyroidism, bone mineral, fracture risk—a meta-analysis,” Thyroid, vol. 13, no. 6, pp. 585–593, 2003. View at Scopus
  8. L. Wartofski, “Osteoporosis: a growing concern for the thyroidologist,” Thyroid Today, vol. 11, pp. 1–11, 1988.
  9. D. T. Baran and L. E. Braverman, “Thyroid hormones and bone mass,” Journal of Clinical Endocrinology and Metabolism, vol. 72, no. 6, pp. 1182–1183, 1991. View at Scopus
  10. K. Zatońska and M. Bolanowski, “The influence of thyrotoxicosis and thyroxine therapy on the risk of osteoporosis,” Polski Merkuriusz Lekarski, vol. 8, no. 47, pp. 356–359, 2000. View at Scopus
  11. Z. E. Belaya, G. A. Melnichenko, L. Y. Rozhinskaya et al., “Subclinical hyperthyroidism of variable etiology and its influence on bone in postmenopausal women,” Hormones, vol. 6, no. 1, pp. 62–70, 2007. View at Scopus
  12. P. Affinito, C. Sorrentino, M. J. Farace et al., “Effects of thyroxine therapy on bone metabolism in postmenopausal women with hypothyroidism,” Acta Obstetricia et Gynecologica Scandinavica, vol. 75, no. 9, pp. 843–848, 1996. View at Scopus
  13. M. Baldini, M. Gallazzi, A. Orsatti, S. Fossati, P. Leonardi, and L. Cantalamessa, “Treatment of benign nodular goitre with mildly suppressive doses of L-thyroxine: effects on bone mineral density and on nodule size,” Journal of Internal Medicine, vol. 251, no. 5, pp. 407–414, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. C. H. Chen, J. F. Chen, B. Y. Yang et al., “Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma,” Journal of the Formosan Medical Association, vol. 103, no. 6, pp. 442–447, 2004. View at Scopus
  15. J. Foldes, G. Tarjan, M. Szathmari, F. Varga, I. Krasznai, and C. Horvath, “Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis?” Clinical Endocrinology, vol. 39, no. 5, pp. 521–527, 1993. View at Scopus
  16. G. Gorres, A. Kaim, A. Otte, M. Gotze, and J. Muller-Brand, “Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma,” European Journal of Nuclear Medicine, vol. 23, no. 6, pp. 690–692, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Hadji, O. Hars, G. Sturm, T. Bauer, G. Emons, and K. D. Schulz, “The effect of long-term, non-suppressive levothyroxine treatment on quantitative ultrasonometry of bone in women,” European Journal of Endocrinology, vol. 142, no. 5, pp. 445–450, 2000. View at Scopus
  18. A. C. Heijckmann, M. S. P. Huijberts, P. Geusens, J. de Vries, P. P. Menheere, and B. H. Wolffenbuttel, “Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma,” European Journal of Endocrinology, vol. 153, no. 1, pp. 23–29, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. A. W. Kung and S. S. Yeung, “Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 3, pp. 1232–1236, 1996. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Larijani, F. Gharibdoost, M. Pajouhi et al., “Effects of levothyroxine suppressive therapy on bone mineral density in premenopausal women,” Journal of Clinical Pharmacy and Therapeutics, vol. 29, no. 1, pp. 1–5, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Mikosch, B. Jauk, H. J. Gallowitsch, W. Pipam, E. Kresnik, and P. Lind, “Suppressive levothyroxine therapy has no significant influence on bone degradation in women with thyroid carcinoma: a comparison with other disorders affecting bone metabolism,” Thyroid, vol. 11, no. 3, pp. 257–263, 2001. View at Scopus
  22. V. Nuzzo, G. Lupoli, A. del Puente et al., “Bone mineral density in premenopausal women receiving levothyroxine suppressive therapy,” Gynecological Endocrinology, vol. 12, no. 5, pp. 333–337, 1998. View at Scopus
  23. S. Sijanovic and I. Karner, “Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone,” Medscape Women's Health, vol. 6, no. 5, p. 3, 2001. View at Scopus
  24. J. Toivonen, R. Tähtelä, K. Laitinen, J. Risteli, and M. J. Välimaki, “Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy,” European Journal of Endocrinology, vol. 138, no. 6, pp. 667–673, 1998. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Jodar, M. Munoz-Torres, F. Escobar-Jimenez, M. Quesada-Charneco, and J. D. Luna Del Castillo, “Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of aetiology and menopause,” Clinical Endocrinology, vol. 47, no. 3, pp. 279–285, 1997. View at Scopus
  26. B. Uzzan, J. Campos, M. Cucherat, P. Nony, J. P. Boissel, and G. Y. Perret, “Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 12, pp. 4278–4289, 1996. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Gharib and E. L. Mazzaferri, “Thyroxine suppressive therapy in patients with nodular thyroid disease,” Annals of Internal Medicine, vol. 128, no. 5, pp. 386–394, 1998. View at Scopus
  28. S. La Vignera, E. Vicari, S. Tumino et al., “L-thyroxin treatment and postmenopausal osteoporosis: relevance of the risk profile present in clinical history,” Minerva Ginecologica, vol. 60, no. 6, pp. 475–484, 2008. View at Scopus